Article

New Study Highlights Factors Linked to Lower Lung Cancer Risk in Patients with COPD

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

It is already known that patients with

chronic obstructive pulmonary disease

(COPD) face a greater risk of dying of lung cancer than age and gender matched controls. According to new research, a

concurrent asthma diagnosis

and the use of inhaled corticosteroids may be associated with a decreased risk of lung cancer in patients with COPD, while the use of acetylsalicylic acid may be linked to an increased risk.

The

study

aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD. Data was collected from primary care medical records and national patient registries in Sweden.

“Both COPD and lung cancer are closely related to the chronic inflammation and oxidative stress induced by smoking,” the study explained. “However, it has been shown that patients with emphysema who have never smoked also have an increased risk of developing lung cancer. Hence, it is likely that the inflammatory process driving the formation of emphysema contributes as a risk factor for lung cancer.”

Click to continue reading on The American Journal of Managed Care.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com